# OnCo record dlbcl (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/dlbcl/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "dlbcl" ;
  schema:name "Diffuse large B-cell lymphoma"@en ;
  schema:description "Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."@en ;
  schema:url <https://onco.cc/cancers/dlbcl/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q2626074> ;
  schema:citation <https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma>, <https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you>, <https://www.maggies.org/support-and-information/>, <https://lymphoma-action.org.uk/information-and-support/types-lymphoma/non-hodgkin-lymphoma/diffuse-large-b-cell-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/car-t-cell-therapy>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/stem-cell-transplants/self-autologous-stem-cell>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/lymphoma-comes-back-relapses-or-doesnt-respond>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/ct-and-petct-scan>, <https://doi.org/10.1200/JCO.2014.55.7561>, <https://www.nhs.uk/conditions/non-hodgkin-lymphoma/treatment/>, <https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin-lymphoma> ;
  onco:tag "heme", "spike" ;
  onco:related <https://onco.cc/pairings/car-t-before-transplant-lbcl/>, <https://onco.cc/pairings/bispecific-plus-adc-lymphoma/>, <https://onco.cc/collections/lymphoma-research-foundation/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/burkitt-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/primary-cns-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/biomarkers/double-hit-rearrangement/>, <https://onco.cc/biomarkers/myc-bcl2-double-expressor/>, <https://onco.cc/biomarkers/bcl2-rearrangement/>, <https://onco.cc/terms/myd88-l265p/>, <https://onco.cc/biomarkers/cd79b-itam-mutation/>, <https://onco.cc/biomarkers/ezh2-y646-mutation/>, <https://onco.cc/biomarkers/ig-tcr-clonality/>, <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/ideas/lymphoma-ev-genetic-subtype-directed-first-line/>, <https://onco.cc/ideas/lymphoma-ev-ctdna-instead-of-the-interim-scan/>, <https://onco.cc/ideas/lymphoma-ev-manufacturing-time-as-a-trial-endpoint/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/g-csf-growth-factors/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/clonality-testing/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/ror1/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/cd47/>, <https://onco.cc/targets/cd79b/>, <https://onco.cc/targets/cd22/>, <https://onco.cc/targets/myd88/>, <https://onco.cc/targets/card11/>, <https://onco.cc/targets/bcl6/>, <https://onco.cc/targets/myc-gene/>, <https://onco.cc/targets/crebbp/>, <https://onco.cc/targets/ep300/>, <https://onco.cc/targets/kmt2d/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/cdkn2a/>, <https://onco.cc/targets/b2m/>, <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/clonoseq/>, <https://onco.cc/drugs/carmustine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/palifermin/>, <https://onco.cc/drugs/rasburicase/>, <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/zynlonta/>, <https://onco.cc/drugs/selinexor/>, <https://onco.cc/drugs/zilovertamab-vedotin/>, <https://onco.cc/drugs/tocilizumab/>, <https://onco.cc/drugs/human-normal-immunoglobulin/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/melphalan/>, <https://onco.cc/drugs/thiotepa/> ;
  onco:companies <https://onco.cc/companies/marker-therapeutics/>, <https://onco.cc/companies/ranok-therapeutics-hangzhou/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/genmab/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/incyte/>, <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/adc-therapeutics/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/foresight-diagnostics/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/md-anderson/>, <https://onco.cc/institutions/dana-farber/>, <https://onco.cc/institutions/mayo-clinic/>, <https://onco.cc/institutions/gustave-roussy/>, <https://onco.cc/institutions/the-christie/> ;
  onco:pathways <https://onco.cc/pathways/apoptosis-bcl2/>, <https://onco.cc/pathways/germinal-centre-reaction/>, <https://onco.cc/pathways/bcr-signalling/>, <https://onco.cc/pathways/inflammation-nfkb/>, <https://onco.cc/pathways/myc/>, <https://onco.cc/pathways/epigenetic-reprogramming/> ;
  onco:terms <https://onco.cc/terms/ipi-score/>, <https://onco.cc/terms/cell-of-origin/>, <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/lymphoma-tx-cns-prophylaxis/>, <https://onco.cc/terms/lymphoma-tx-maintenance/>, <https://onco.cc/terms/lymphoma-tx-car-t-pathway/>, <https://onco.cc/terms/lymphoma-tx-bispecific-step-up/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/lymphoma-tx-tumour-lysis/>, <https://onco.cc/terms/lymphoma-tx-hepatitis-b-reactivation/>, <https://onco.cc/terms/lymphoma-tx-pjp-and-infection-prophylaxis/>, <https://onco.cc/terms/lymphoma-tx-immunoglobulin-replacement/>, <https://onco.cc/terms/lymphoma-tx-crs-icans/>, <https://onco.cc/terms/lymphoma-tx-fertility-preservation/>, <https://onco.cc/terms/lymphoma-tx-uk-versus-us/>, <https://onco.cc/terms/lymphoma-tx-uk-access/>, <https://onco.cc/terms/lymphoma-tx-failed-and-negative/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/central-venous-access/>, <https://onco.cc/terms/hypogammaglobulinaemia/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/lymphoma-decision-transplant-or-car-t/>, <https://onco.cc/terms/lymphoma-decision-fertility-timing/>, <https://onco.cc/terms/lymphoma-decision-trial/>, <https://onco.cc/terms/lymphoma-decision-local-or-car-t-centre/>, <https://onco.cc/terms/lymphoma-living-fatigue/>, <https://onco.cc/terms/lymphoma-living-infection-years-after/>, <https://onco.cc/terms/lymphoma-living-vaccinations/>, <https://onco.cc/terms/lymphoma-living-scanxiety-and-surveillance/>, <https://onco.cc/terms/lymphoma-living-returning-to-work/>, <https://onco.cc/terms/tumor-lysis-syndrome/>, <https://onco.cc/terms/deauville/>, <https://onco.cc/terms/lymphoma-bio-cell-of-origin-in-practice/>, <https://onco.cc/terms/lymphoma-bio-lymphgen/>, <https://onco.cc/terms/lymphoma-bio-germinal-centre/>, <https://onco.cc/terms/lymphoma-bio-antigen-escape/>, <https://onco.cc/terms/lymphoma-bio-lineage-antigen-cost/> ;
  onco:trials <https://onco.cc/trials/nct07011056/>, <https://onco.cc/trials/nct07570823/>, <https://onco.cc/trials/nct06929624/>, <https://onco.cc/trials/nct07409428/>, <https://onco.cc/trials/nct07188558/>, <https://onco.cc/trials/nct07215585/>, <https://onco.cc/trials/nct06792253/>, <https://onco.cc/trials/nct04442022/>, <https://onco.cc/trials/nct04529772/>, <https://onco.cc/trials/nct04094311/>, <https://onco.cc/trials/nct06717347/>, <https://onco.cc/trials/nct07226752/>, <https://onco.cc/trials/nct04384484/>, <https://onco.cc/trials/nct05429268/>, <https://onco.cc/trials/nct06508658/>, <https://onco.cc/trials/nct01804686/>, <https://onco.cc/trials/nct06091865/>, <https://onco.cc/trials/nct04404283/>, <https://onco.cc/trials/l-mind/>, <https://onco.cc/trials/zuma-1/>, <https://onco.cc/trials/polarix/>, <https://onco.cc/trials/frontmind/>, <https://onco.cc/trials/zuma-7/>, <https://onco.cc/trials/transform/>, <https://onco.cc/trials/belinda/>, <https://onco.cc/trials/starglo/>, <https://onco.cc/trials/sunmo/>, <https://onco.cc/trials/epcore-dlbcl-1/>, <https://onco.cc/trials/epcore-dlbcl-2/>, <https://onco.cc/trials/lotis-2/>, <https://onco.cc/trials/waveline-003/>, <https://onco.cc/trials/golseek-1/>, <https://onco.cc/trials/flyer/>, <https://onco.cc/trials/calgb-50303/>, <https://onco.cc/trials/goya/>, <https://onco.cc/trials/remarc/>, <https://onco.cc/trials/polargo/>, <https://onco.cc/trials/juliet/>, <https://onco.cc/trials/transcend-nhl-001/>, <https://onco.cc/trials/polar-bear/>, <https://onco.cc/trials/arched/> ;
  onco:journals <https://onco.cc/journals/blood-cancer-discovery/>, <https://onco.cc/journals/blood-cancer-journal/>, <https://onco.cc/journals/clinical-lymphoma-myeloma-and-leukemia/>, <https://onco.cc/journals/current-hematologic-malignancy-reports/>, <https://onco.cc/journals/haematologica/>, <https://onco.cc/journals/hematological-oncology/>, <https://onco.cc/journals/leukemia-and-lymphoma/> ;
  onco:pipeline <https://onco.cc/drugs/zilovertamab-vedotin/>, <https://onco.cc/drugs/abexinostat/>, <https://onco.cc/drugs/dzd8586/>, <https://onco.cc/drugs/rocbrutinib/>, <https://onco.cc/drugs/mk-1045/>, <https://onco.cc/drugs/purinostat/>, <https://onco.cc/drugs/sctb35/>, <https://onco.cc/drugs/shr-a1912/>, <https://onco.cc/drugs/hmpl-760/>, <https://onco.cc/drugs/rondecabtagene-autoleucel/>, <https://onco.cc/drugs/azd0486/>, <https://onco.cc/drugs/ifupinostat/>, <https://onco.cc/drugs/tqb2825/>, <https://onco.cc/drugs/krt-232/>, <https://onco.cc/drugs/zamtocabtagene-autoleucel/>, <https://onco.cc/drugs/tc011/>, <https://onco.cc/drugs/crc01/>, <https://onco.cc/drugs/jnj-90014496/>, <https://onco.cc/drugs/ctx112/>, <https://onco.cc/drugs/allo-647/>, <https://onco.cc/trials/frontmind/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/trials/epcore-dlbcl-2/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/golcadomide/>, <https://onco.cc/trials/golseek-1/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/trials/sunmo/>, <https://onco.cc/drugs/odronextamab/>, <https://onco.cc/trials/waveline-003/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/ideas/idea-ctdna-guided-dlbcl-frontline/>, <https://onco.cc/ideas/idea-bispecific-vs-car-t-second-line/> ;
  onco:standardOfCare <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/terms/ipi-score/>, <https://onco.cc/trials/polarix/>, <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/trials/frontmind/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/trials/zuma-7/>, <https://onco.cc/trials/transform/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/zynlonta/>, <https://onco.cc/trials/sunmo/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/zynlonta/>, <https://onco.cc/drugs/zilovertamab-vedotin/>, <https://onco.cc/trials/waveline-003/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/ipi-score/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/terms/lymphoma-tx-cns-prophylaxis/>, <https://onco.cc/terms/lymphoma-tx-hepatitis-b-reactivation/>, <https://onco.cc/terms/lymphoma-tx-fertility-preservation/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/terms/ipi-score/>, <https://onco.cc/terms/lymphoma-tx-failed-and-negative/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/trials/polarix/>, <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/trials/frontmind/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/terms/ipi-score/>, <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/terms/lymphoma-tx-cns-prophylaxis/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/technologies/g-csf-growth-factors/>, <https://onco.cc/terms/lymphoma-tx-pjp-and-infection-prophylaxis/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/terms/lymphoma-tx-cns-prophylaxis/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/terms/intrathecal-therapy/>, <https://onco.cc/terms/ipi-score/>, <https://onco.cc/terms/cns-penetration/>, <https://onco.cc/trials/zuma-7/>, <https://onco.cc/trials/transform/>, <https://onco.cc/trials/belinda/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/terms/lymphoma-tx-car-t-pathway/>, <https://onco.cc/terms/lymphoma-tx-crs-icans/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/carmustine/>, <https://onco.cc/drugs/melphalan/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/trials/starglo/>, <https://onco.cc/trials/epcore-dlbcl-1/>, <https://onco.cc/trials/sunmo/>, <https://onco.cc/trials/l-mind/>, <https://onco.cc/trials/lotis-2/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/drugs/zynlonta/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/terms/lymphoma-tx-bispecific-step-up/>, <https://onco.cc/trials/zuma-1/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/zynlonta/>, <https://onco.cc/drugs/selinexor/>, <https://onco.cc/drugs/zilovertamab-vedotin/>, <https://onco.cc/trials/waveline-003/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/terms/lymphoma-tx-bispecific-step-up/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/deauville/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/terms/cardiotoxicity/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/lymphoma-tx-hodgkin-late-effects/> .